Method for estimating cause of blood coagulation anomaly by analysis of deviation waveform

The method analyzes divergence waveforms from blood coagulation reaction curves to efficiently detect coagulation abnormalities in patients taking DOACs, addressing the limitations of conventional tests by providing rapid and accurate assessments of coagulation issues.

WO2024248019A1PCT designated stage expired Publication Date: 2024-12-05SEKISUI MEDICAL CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/019652
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2024-05-29
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Conventional blood coagulation tests are laborious and time-consuming, failing to promptly detect coagulation abnormalities in patients taking Directly Acting Oral Anticoagulants (DOACs), which can lead to inappropriate treatment during emergencies.

Method used

A method analyzing divergence waveforms from blood coagulation reaction curves to estimate coagulation abnormalities by calculating parameters such as gT(S), gH(S), gB(S), and RgB(S1/S2), allowing for the detection of DOACs and other coagulation issues without prolonged clotting times.

Benefits of technology

Enables rapid estimation of coagulation abnormality causes, including DOACs administration, reducing the risk of inappropriate treatment by analyzing blood coagulation reaction curves, thereby improving diagnostic efficiency and patient safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024019652_05122024_PF_FP_ABST
    Figure JP2024019652_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a method for estimating a cause of a coagulation anomaly in a blood specimen, said method comprising calculating a deviation curve D(i) of a subject blood specimen, calculating a parameter which reflects the shape of said D(i), and estimating a cause of a coagulation anomaly in said subject blood specimen on the basis of said parameter, wherein D(i)=P(i)-Pn(i) where: i represents the number of measured points or time; P(i) is a curve obtained by converting measurement data of a coagulation reaction of said subject blood specimen into a relative value so that the minimum value is 0, and the maximum value is A; Pn(i) is a curve obtained by shifting P'(i) so that a rise point thereof is aligned with a prescribed point X, where said P'(i) is a curve obtained by converting measurement data of a coagulation reaction of a reference specimen into a relative value so that the minimum value is 0, and the maximum value is A; A>0; and X is 5-15 seconds or the number of measured points corresponding thereto.
Need to check novelty before this filing date? Find Prior Art

Description

A method for estimating the causes of blood coagulation disorders by analyzing divergent waveforms

[0001] The present invention relates to a method for estimating the cause of blood coagulation abnormalities.

[0002] A blood coagulation test is a test for diagnosing a patient's blood coagulation ability by adding a specific reagent to a patient's blood sample and measuring the blood coagulation time, etc. Typical examples of blood coagulation times include prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time. Abnormal blood coagulation ability causes a prolongation of the coagulation time. Factors that cause abnormal blood coagulation ability include the effects of anticoagulants, a decrease in coagulation-related components, a congenital deficiency of blood coagulation factors, and the acquired appearance of autoantibodies that inhibit the coagulation reaction.

[0003] Conventionally, when a blood coagulation test shows a prolonged clotting time of a test sample, generally if the sample is not suspected of containing an anticoagulant, a cross-mixing test is performed to determine the cause of the prolonged clotting time. In the cross-mixing test, a mixed sample of the test sample and a normal sample is prepared, and the APTT (immediate reaction) immediately after mixing and the APTT (delayed reaction) after 2 hours of incubation at 37°C are measured. Based on the patterns of the immediate and delayed reactions, it is determined whether the cause of the prolonged APTT of the test sample is a coagulation factor inhibitor (anticoagulant), lupus anticoagulant (LA), or a coagulation factor deficiency such as hemophilia. However, as described above, conventional cross-mixing tests are extremely time-consuming and laborious.

[0004] Directly Acting Oral Anticoagulants (DOACs) are oral anticoagulants that inhibit thrombin or activated factor X and are administered prophylactically to patients at risk of thrombosis. Blood samples taken from patients receiving DOACs usually have a prolonged clotting time, but there are cases where the clotting time is within the normal range, which may pose a serious risk to the patient. For example, if a patient receiving DOACs is rushed to the hospital after a traffic accident or other incident and undergoes surgery, if a prolonged clotting time is not observed in a standard preoperative coagulation test, a doctor who is unaware that the patient is receiving DOACs will not recognize that the patient has an abnormality in coagulation ability and will be unable to provide appropriate treatment.

[0005] Patent Documents 1 to 4 describe the calculation of parameters such as the weighted average time, weighted average height, peak width, and base line length of the coagulation rate curve of a blood sample, and the use of these parameters for estimating the cause of prolongation of the blood coagulation time, evaluating the deficiency of coagulation factors, calculating the blood coagulation time, etc. Patent Document 5 describes the calculation of parameters such as the weighted average time, weighted average height, peak width, and base line length of the coagulation rate curve of a blood sample, and the use of these parameters for estimating the cause of prolongation of the blood coagulation time, evaluating the deficiency of coagulation factors, calculating the blood coagulation time, etc. k and q k Calculate the p k and q k Patent Document 6 describes a method for estimating factors that prolong blood coagulation time based on the shape of a function T(X) that represents the time it takes for a coagulation reaction curve P(i) of a blood sample to reach X% of the coagulation reaction end point Pe.

[0006] International Publication No. 2020 / 101025 International Publication No. 2020 / 158948 International Publication No. 2020 / 218425 International Publication No. 2021 / 177452 International Publication No. 2022 / 054819 International Publication No. 2022 / 186381

[0007] The present invention provides a new method for estimating the cause of coagulation abnormalities in a blood sample.

[0008] That is, the present invention provides the following: [1] A method for estimating causes of coagulation abnormalities in a blood sample, comprising: calculating a deviation curve D(i) of a test blood sample; calculating parameters reflecting the shape of D(i); and estimating causes of coagulation abnormalities in the test blood sample based on the parameters, wherein: D(i) = P(i) - Pn(i); i represents the number of measurement points or time; P(i) is a curve obtained by relativizing the measurement data of the coagulation reaction of the test blood sample so that it has a minimum value of 0 and a maximum value of A; Pn(i) is a curve obtained by shifting P'(i) so that its rising point coincides with a predetermined point X, and P'(i) is a curve obtained by relativizing the measurement data of the coagulation reaction of a reference sample so that it has a minimum value of 0 and a maximum value of A; A > 0; and X is 5 to 15 seconds, or the number of measurement points corresponding thereto. [2] The parameter reflecting the shape of D(i) is at least one selected from the group consisting of gT(S), gH(S), gB(S), gAB(S), and RgB(S1 / S2), wherein gT(S) and gH(S) are respectively represented by the following formulas: wherein t1 and t2 are the minimum and maximum values ​​of i that satisfy D(i)≧Dmax×S(%), where Dmax is the maximum value of D(i), and 0<S<100, provided that when D(i)<Dmax×S(%) in the formula, i=0 and D(i)=0 are considered; gB(S) represents the time or the number of measurement points between t1 and t2 that satisfy D(i)≧Dmax×S(%); gAB(S)=gH(S) / gB(S); RgB(S1 / S2)=gB(S1) / gB(S2), where 0<S1<100 and 0<S2<100, provided that S1≠S2. [3] The method of [2], comprising calculating at least one selected from the group consisting of gB(S) and gAB(S) when the clotting time of the test blood sample is not prolonged. [4] The method of [3], comprising inferring that the test blood sample is DOACs-positive when gB(S) is at or above a threshold value or when gAB(S) is at or below a threshold value. [5] The method of [2], comprising calculating at least one selected from the group consisting of gAB(S) and RgB(S1 / S2) when the clotting time of the test blood sample is prolonged. [6] The method of [5], comprising inferring that the test blood sample is coagulation factor inhibitor-positive when gAB(S) is at or below a threshold value. [7] The method of [5], comprising inferring that the test blood sample is heparin-positive when S1<S2 and RgB (S1 / S2) is at or below a threshold, or when S1>S2 and RgB (S1 / S2) is at or above a threshold. [8] The method of [5], comprising inferring that the test blood sample is coagulation factor inhibitor-positive when gAB (S) is at or below a threshold, inferring that the test blood sample is heparin-positive when S1<S2 and RgB (S1 / S2) is at or below a threshold, or when S1>S2 and RgB (S1 / S2) is at or above a threshold, and inferring whether a test blood sample that was not inferred to be coagulation factor inhibitor-positive or heparin-positive is lupus anticoagulant-positive or has a coagulation factor deficiency.[9] The method comprises preparing a mixed sample of the test blood sample that is not suspected to be positive for a coagulation factor inhibitor or heparin and a normal sample; calculating a deviation curve Dm(i) of the mixed sample and a deviation curve Ds(i) of the normal sample; calculating gAB(S) for Dm(i) and Ds(i); and calculating a parameter R(S), wherein: Dm(i)=Pm(i)-Pn(i); Ds(i)=Ps(i)-Pn(i); Pm(i) is a curve obtained by relativizing the measurement data of the coagulation reaction of the mixed sample so that the minimum value is 0 and the maximum value is A; Ps(i) is a curve obtained by relativizing the measurement data of the coagulation reaction of the normal sample so that the minimum value is 0 and the maximum value is A; Pn(i) and A are as defined above; and gAB(S) for Ds(i) is represented by the following formula: gAB(S) for Ds(i) = [gH(S) for Ds(i)] ÷ [gB(S) for Ds(i)] where, (In formula (I), t1 and t2 are the minimum and maximum values ​​of i that satisfy Ds(i) ≥ [maximum value of Ds(i) × S(%)], and 0 < S < 100, provided that when Ds(i) < [maximum value of Ds(i) × S(%)], it is considered that i = 0 and Ds(i) = 0), gB(S) for Ds(i) represents the time or number of measurement points that satisfy Ds(i) ≥ [maximum value of Ds(i) × S(%)] between t1 and t2; gAB(S) for Dm(i) is expressed by the following formula, gAB(S) for Dm(i) = [gH(S) for Dm(i)] ÷ [gB(S) for Dm(i)], where, (In formula (II), t1 and t2 are the minimum and maximum values ​​of i, respectively, that satisfy Dm(i)≧[maximum value of Dm(i)×S(%)], and 0<S<100, with the proviso that when Dm(i)<[maximum value of Dm(i)×S(%)], i=0 and Dm(i)=0 are considered), gB(S) for Dm(i) represents the time or number of measurement points that satisfy Dm(i)≧[maximum value of Dm(i)×S(%)] between t1 and t2; R(S)={(gAB(S) for Ds(i))+(gAB(S) for D(i))} / 2−(gAB(S) for Dm(i)). The method according to [8],

[10] The method of [9], further comprising: determining whether the test blood sample is lupus anticoagulant-positive if R(S) is greater than or equal to a threshold value; or determining whether the test blood sample is coagulation factor-deficient if R(S) is less than or equal to a threshold value.

[11] The method of [1], further comprising calculating the clotting time of the test blood sample.

[0009] According to the present invention, when the clotting time of a test blood sample is prolonged, the cause of the coagulation abnormality that caused the prolongation of the clotting time can be estimated.Furthermore, according to the present invention, blood samples administered with DOACs can be detected from test blood samples that do not have a prolonged clotting time and in which coagulation abnormalities cannot be detected by conventional coagulation tests.

[0010] P(i) and Pn(i) of the reference sample (RP). P(i) and D(i) obtained from a clotting factor inhibitor-positive (Inh) sample (A), a heparin-positive (Hep) sample (B), and a DOACs-positive (DOACs) sample (C). Left: P(i) and Pn(i), Right: D(i). gB50 (A), gB60 (B), gB70 (C), and gAB60 (D) of a DOACs-positive (DOACs) sample and other samples with normal APTT. gAB05 of a clotting factor inhibitor-positive (Inh) sample and other samples with factors prolonging the APTT. gB05 / gB90 of a heparin-positive (Hep) sample and other samples with factors prolonging the APTT. R(S) of mixed specimens derived from LA positive (LA) specimens and clotting factor deficiency (Def) specimens (S = 5, 10, 20, 30, 40, and 50). R(S) of mixed specimens derived from LA positive (LA) specimens and clotting factor deficiency (Def) specimens (S = 60, 70, 80, and 90).

[0011] In blood coagulation tests, a specific reagent is added to a test blood sample, and the subsequent blood coagulation reaction is measured to determine the blood coagulation time from the coagulation reaction. In this specification, the blood coagulation reaction, blood coagulation time, and blood sample may be referred to simply as "coagulation reaction," "coagulation time," and "sample," respectively. Coagulation reactions are measured using common methods, such as optical methods that measure scattered light intensity, transmittance, and absorbance, or mechanical methods that measure plasma viscosity. The coagulation reaction curve of a normal sample generally exhibits a sigmoidal shape, depending on the measurement method. For example, the coagulation reaction curve based on the scattered light intensity of a normal sample typically rises sharply after a certain time has elapsed since the addition of the reagent, as coagulation progresses, and then plateaus as the coagulation reaction approaches completion. On the other hand, the coagulation reaction curve of an abnormal sample exhibiting a blood coagulation abnormality exhibits various shapes, such as a delayed rise time or a gradual rise, depending on the cause of the abnormality. As a result, abnormal samples often have a prolonged coagulation time compared to normal samples. A prolonged coagulation time is an indicator of the presence or absence of a coagulation abnormality. On the other hand, the type of coagulation abnormality factor (factor that prolongs the coagulation time) cannot be estimated from the coagulation time.

[0012] When a blood coagulation test reveals a prolongation of the clotting time, e.g., APTT, a heparin contamination is typically suspected as the cause (e.g., heparin administration, blood collection from a heparin-locked infusion line, blood collection after dialysis, etc.). Heparin-contaminated blood samples can be confirmed by the shortening of the clotting time with protamine sulfate, which has a heparin-neutralizing effect. If heparin contamination is not suspected in the blood sample, the presence or absence of administration of DOACs or warfarin is confirmed, if possible, and then a cross-mixing test is performed to determine the cause of the prolongation of the clotting time (hereinafter simply referred to as the "prolongation cause"). Specifically, it is determined whether the prolongation of the APTT is due to a coagulation factor inhibitor (anticoagulant), lupus anticoagulant (LA), or a coagulation factor deficiency such as hemophilia. In the cross-mixing test, the APTT (immediate reaction) immediately after mixing of a normal sample, a test sample, and a mixed sample of the test sample and a normal sample, and the APTT (delayed reaction) after 2 hours of incubation at 37°C are measured. Based on the patterns of these immediate and delayed reactions, the cause of APTT prolongation is determined. In conventional methods, the cause of prolongation cannot be determined unless a cross-mixing test is performed separately from the measurement of clotting time. However, the cross-mixing test is time-consuming and laborious because it requires measurement of the immediate reaction of the mixed sample and the delayed reaction after 2 hours of incubation.

[0013] As in the above-mentioned Patent Documents 1 to 5, methods for obtaining data on factors that cause prolongation without relying on a cross-mixing test have been proposed. The evaluation of factors that cause prolongation in these documents utilizes the derivative curve of the coagulation reaction curve, i.e., the coagulation rate (first derivative) and the coagulation acceleration (second derivative). Patent Document 6 does not use the derivative curves described above, but instead extracts information on factors that cause prolongation using a function T(X) calculated based on the coagulation reaction curve. However, few attempts have been made to extract information on factors that cause prolongation by focusing on the coagulation reaction curve.

[0014] [Method for Estimating Causes of Prolongation of Clotting Time] The present invention relates to a method for estimating causes of coagulation abnormalities in blood samples. In the method of the present invention, the causes of coagulation abnormalities are estimated by analyzing the difference between the coagulation reaction curves of a test sample and a reference sample.

[0015] 1. Coagulation Reaction Measurement In coagulation reaction measurement, the coagulation reaction of a test sample is measured. A coagulation reaction curve can be obtained from the time-series data of the coagulation reaction obtained by this measurement. The coagulation reaction measurement can be performed according to the procedures of general coagulation reaction measurements such as those performed to measure coagulation times such as prothrombin time (PT) and activated partial thromboplastin time (APTT), or to measure fibrinogen concentration (Fbg). In the following specification, the method of the present invention will be mainly described based on coagulation reaction measurement using APTT measurement. Those skilled in the art can modify the method of the present invention to other measurement methods (for example, coagulation reaction measurement using PT measurement).

[0016] In coagulation reaction measurement, the test blood sample is preferably plasma from the subject. An anticoagulant commonly used in coagulation tests may be added to the sample. For example, blood is collected using a blood collection tube containing sodium citrate, and then centrifuged to obtain plasma.

[0017] In coagulation reaction measurement, a coagulation time measurement reagent is added to the test sample to initiate the blood coagulation reaction. The coagulation reaction of the mixture after the addition of the reagent can be measured. The reagent used can be selected arbitrarily depending on the purpose of the measurement. Various reagents for measuring coagulation time are commercially available (e.g., APTT reagent Coagpia APTT-N; manufactured by Sekisui Medical Co., Ltd.). Coagulation reaction can be measured using common means, such as optical means for measuring scattered light, transmittance, absorbance, etc., or mechanical means for measuring plasma viscosity. The start of the coagulation reaction is typically defined as the time when the sample is mixed with the reagent to initiate the coagulation reaction, but other timings may also be defined as the reaction start time. The measurement time of the coagulation reaction can be arbitrarily determined, for example, from several tens of seconds to approximately 7 minutes from the time when the sample and reagent are mixed. During the measurement time, the progress of the coagulation reaction can be repeatedly measured at predetermined intervals (photometrically, if detected optically). For example, measurements can be performed at 0.1-second intervals. The temperature of the mixture during the measurement is set under normal conditions, for example, 30° C. to 40° C., preferably 35° C. to 39° C. In addition, various measurement conditions can be appropriately set depending on the test specimen, reagent, measurement means, etc.

[0018] The series of operations in the coagulation reaction measurement described above can be performed using an automatic analyzer. An example of an automatic analyzer is the CP3000 automatic blood coagulation analyzer (manufactured by Sekisui Medical Co., Ltd.). Alternatively, some of the operations may be performed manually. For example, the preparation of the test sample may be performed manually, and the subsequent operations may be performed using the automatic analyzer.

[0019] 2. Clotting Reaction Curve Measurement data of the test specimen is obtained by coagulation reaction measurement. This data reflects the coagulation reaction process of the test specimen. For example, data (hereinafter referred to as reaction data C(i)) showing the change over time in the progress of the coagulation reaction (e.g., the amount of scattered light) after the addition of calcium chloride solution from a mixture containing the test specimen and a coagulation time measurement reagent is obtained.

[0020] If necessary, the reaction data C(i) is subjected to preprocessing. The preprocessing may include a smoothing process to remove noise, or zero-point adjustment. Any known noise removal method may be used for the smoothing process. Furthermore, in a mixed solution containing a test sample, the amount of scattered light at the start of the reaction (time 0) is greater than 0. By the zero-point adjustment, the amount of scattered light at time 0 can be adjusted to 0. The zero-point adjustment is preferably performed after the smoothing process.

[0021] Next, the reaction data C(i) is converted into a relative value to obtain the coagulation reaction curve P(i) used in the present invention. Preferably, P(i) is calculated from C(i) according to the following formula (1). In formula (1), Cmax and Cmin represent the maximum and minimum values ​​of C(i), respectively, Crange represents the range of change in C(i) (i.e., Cmax-Cmin), and A is an arbitrary value that corresponds to the maximum value of P(i). i represents the time from the start of the coagulation reaction of the sample (hereinafter simply referred to as "time") or the number of measurement points from the start of the coagulation reaction of the sample (hereinafter simply referred to as "number of measurement points"). P(i)=[(C(i)-Cmin) / Crange]×A (1) (A is arbitrary, provided that A>0, for example, A=100)

[0022] P(i) based on the amount of scattered light is typically sigmoidal. On the other hand, P(i) based on the amount of transmitted light is typically inverse sigmoidal. In the following description, the procedure of the method of the present invention will be explained using P(i) based on the amount of scattered light.

[0023] 3. Deviation Curve In the present invention, a deviation curve for a test sample is obtained from the coagulation reaction curve P(i). The deviation curve represents the difference between P(i) of the test sample and the reference curve Pn(i). In this specification, the deviation curve is represented by D(i). D(i) for a test sample is expressed by the following formula (2): D(i) = P(i) of test sample - Pn(i) (2)

[0024] The reference curve Pn(i) is created based on P(i) from a reference sample (hereinafter referred to as P'(i)). The reference sample can be a blood sample from a person without a blood coagulation disorder, such as a blood sample collected from a healthy person, preferably plasma, a pooled sample thereof, or commercially available normal plasma (hereinafter collectively referred to as a "normal sample"). Preferably, the reference sample is a sample with a clotting time (APTT) of 24 to 39 seconds, more preferably 24 to 30 seconds. Alternatively, P'(i) can be the P(i) from the sample with the shortest clotting time among blood samples from a person without a blood coagulation disorder, or the average value of P(i) from blood samples from a person without a blood coagulation disorder.

[0025] Pn(i) is a curve obtained by shifting P'(i) so that its rising point (time point or the number of measurement points corresponding thereto) coincides with a predetermined point X. The predetermined point X is basically a point earlier than the rising point, and preferably X=5 to 15 seconds, or the number of measurement points corresponding thereto. The rising point of P'(i) can be detected as the time point or the number of measurement points at which P(i) reaches 1 to 5%, for example 2%, of its maximum value. When the difference between the detected rising point and the predetermined point X is k, Pn(i) is expressed by the following formula (3): Pn(i)=P'(i+k) (3) Therefore, in one embodiment, D(i) can be expressed by the following formula (2)': D(i)=P(i)-P'(i+k) (2)'

[0026] 4. Evaluation of the shape of the deviation curve

[0027] In the present invention, parameters that reflect the shape of the deviation curve D(i) of the test sample obtained above can be calculated. Examples of such parameters include weighted average time, weighted average height, and peak width.

[0028] In one embodiment, the calculated parameters are the weighted average time and / or weighted average height in a predetermined calculation range of the deviation curve D(i) of the test sample. The calculation range is defined as a region in D(i) that satisfies D(i) ≧ Dmax × S (%), where Dmax represents the maximum value of D(i) and 0 < S < 100. Preferably, 1 ≦ S ≦ 99, more preferably 5 ≦ S ≦ 95. Therefore, the calculation range and its weighted average time and weighted average height vary depending on S. Multiple weighted average times and weighted average heights depending on S can be calculated. In this specification, the weighted average time and weighted average height depending on S are represented as gT(S) and gH(S), respectively.

[0029] gT(S) and gH(S) are expressed by the following formulas (4) and (5), respectively. In the formula, t1 and t2 are the minimum and maximum values ​​of i that satisfy D(i)≧Dmax×S(%), provided that when D(i)<Dmax×S(%), it is considered that i=0 and D(i)=0.

[0030] In one embodiment, the calculated parameter is the peak width in a predetermined calculation range of the deviation curve D(i) of the test sample, which represents the time or the number of measurement points between t1 and t2 where D(i)≧Dmax×S(%) is satisfied. Therefore, the peak width varies depending on S. Multiple peak widths according to S can be calculated. In this specification, the peak width according to S is represented as gB(S).

[0031] In one embodiment, the calculated parameter is the ratio of two gB(S) for different S, specifically expressed as gB(S1) / gB(S2), hereinafter also referred to as RgB(S1 / S2). Here, S1 and S2 are each defined in the same way as S above, except that S1≠S2. Preferably, |S1-S2|≧20, for example, 5≦S1≦40 and 60≦S2≦90, or 60≦S1≦90 and 5≦S2≦40.

[0032] In one embodiment, the calculated parameter is the ratio of gB(S) to gH(S), specifically expressed as gH(S) / gB(S), where preferably 5<S<90. In this specification, gH(S) / gB(S) is also referred to as the sharpness ratio gAB(S).

[0033] 5. Estimation of the Cause of Coagulation Abnormality The cause of coagulation abnormality in a test sample can be estimated based on parameters reflecting the shape of D(i) described above. In one embodiment, the present invention can estimate whether a test sample without prolonged coagulation time is normal or is receiving DOACs (DOACs positive). In another embodiment, the present invention can estimate the cause of coagulation abnormality that caused the prolongation of coagulation time in a test sample with prolonged coagulation time. Causes of coagulation abnormality estimated by the present invention include coagulation factor deficiency, lupus anticoagulant positivity, coagulation factor inhibitor positivity, and heparin positivity.

[0034] (1. Calculation of Clotting Time) Therefore, in the present invention, the clotting time of the test sample is calculated before the cause of the clotting abnormality is estimated. The calculation of the clotting time can be performed by any method. Examples of methods for calculating the clotting time include a method in which the clotting time is calculated as the time when P(i) reaches N% of its maximum value; a method in which the clotting time is calculated as the time when the first derivative curve of P reaches N% of its maximum value; a method in which the time when the ratio of the integrated value of P(i) in a short time period reaches a predetermined value is set as the calculation starting point Te, and the time when P(i) reaches N% of P(Te) is calculated as the clotting time (Japanese Patent Laid-Open Publication No. 6-249855); Examples of methods include, but are not limited to, a method of calculating the clotting time based on a change in the clotting time (see Patent Application No. 2019-237427); a method of calculating the clotting time based on a weighted average time of the first derivative curve of P (see Patent Application No. 2020-039344); and a method of calculating the clotting time from the point Te when the first derivative curve of P reaches a predetermined value after reaching its maximum value, where Te is the calculation starting point, when P(i) reaches N% of P(Te) (see Patent Application No. 2020-068877).

[0035] (2. Estimation of DOACs Positivity) If the clotting time of the test sample is not prolonged, it is estimated whether the sample is normal or DOACs positive based on a parameter reflecting the shape of D(i). In one embodiment, the parameter is gB(S). The gB(S) of DOACs-positive samples tends to be larger than that of normal samples. Therefore, if the gB(S) of the test sample is at or above a predetermined threshold, the sample can be estimated to be DOACs positive. The threshold can be determined based on gB(S) obtained from a group of known DOACs-positive samples. For example, the threshold can be set as [mean value - k x SD] (preferably k = 0.5 to 3) of gB(S) of a group of known DOACs-positive samples. On the other hand, if the gB(S) of the test sample is at or below a predetermined threshold, the sample can be estimated to be not DOACs-positive (or normal). In another embodiment, the parameter is gAB(S). The gAB(S) of DOACs-positive samples tends to be smaller than that of normal samples. Therefore, if the gAB(S) of a test sample is at or below a predetermined threshold, the sample can be presumed to be DOACs-positive. The threshold can be determined based on the gAB(S) obtained from a group of known DOACs-positive samples. For example, the threshold can be set as the [mean value + k × SD] (preferably k = 0.5 to 3) of the gAB(S) of a group of known DOACs-positive samples. On the other hand, if the gAB(S) of a test sample is at or above a predetermined threshold, the sample can be presumed not to be DOACs-positive (or normal).

[0036] (3. Estimation of the Cause of Coagulation Abnormality) If the clotting time of a test sample is prolonged, the sample has a coagulation abnormality that causes a prolongation of the clotting time. The cause of the coagulation abnormality of the test sample is estimated based on the parameters reflecting the shape of D(i).

[0037] (3.1. Prediction of Heparin Positivity) In one embodiment, the parameter is RgB (S1 / S2). When S1 < S2, the RgB (S1 / S2) of a heparin-positive sample tends to be smaller than that of samples with other coagulation disorders. Therefore, if the RgB (S1 / S2) of a test sample is at or below a predetermined threshold, the sample can be predicted to be heparin-positive (Hep). The threshold can be determined based on the RgB (S1 / S2) obtained from a group of known heparin-positive samples. For example, the threshold can be set as [mean value + k × SD] (preferably k = 0.5 to 3) of the RgB (S1 / S2) of a group of known heparin-positive samples. On the other hand, when S1>S2, if the RgB(S1 / S2) of the test sample is equal to or greater than a predetermined threshold, the sample can be estimated to be heparin positive (Hep). The threshold can be set, for example, as the [mean value-k×SD] (preferably k=0.5 to 3) of the RgB(S1 / S2) of a known group of heparin-positive samples.

[0038] (3.2. Prediction of Inhibitor Positivity) In one embodiment, the parameter is gAB(S). The gAB(S) of a coagulation factor inhibitor-positive sample tends to be smaller than that of samples with other coagulation abnormalities. Therefore, if the gAB(S) of a test sample is at or below a predetermined threshold, the sample can be predicted to be coagulation factor inhibitor-positive (Inh). The threshold can be determined based on the gAB(S) obtained from a group of known coagulation factor inhibitor-positive samples. For example, the threshold can be set as [mean value + k × SD] (preferably k = 0.5 to 3) of the gAB(S) of a group of known coagulation factor inhibitor-positive samples.

[0039] (3.3. Estimation of Lupus Anticoagulant Positivity and Coagulation Factor Deficiency) In one embodiment, the cause of coagulation abnormality in a test sample that was not estimated as heparin positive (Hep) or coagulation factor inhibitor positive (Inh) by the above procedure is estimated. Specifically, the sample is estimated to be lupus anticoagulant positive (LA) or coagulation factor deficient (Def).

[0040] In estimating LA and Def, a mixed sample of a test sample and a normal sample is prepared, and a deviation curve D(i) for the mixed sample is obtained. Separately, D(i) for the test sample and the normal sample is obtained. gAB(S) for each D(i) is calculated. The procedure for calculating gAB(S) for the test sample is as described above.

[0041] In preparing a mixed sample, a test sample and a normal sample are mixed at a predetermined ratio. As the normal sample, as described above, for example, a blood sample collected from a healthy subject, preferably plasma, a pooled sample thereof, or commercially available normal plasma can be used. The mixing ratio of the test sample and the normal sample, with a total volume of 10, may be in the range of test sample:normal sample = 1:9 to 9:1, preferably 4:6 to 6:4, and more preferably 5:5. The coagulation reaction of the mixed sample is measured to obtain P(i) of the mixed sample. Here, P(i) of the mixed sample is also referred to as Pm(i). D(i) of the mixed sample is calculated from Pm(i). Here, D(i) of the mixed sample is also referred to as Dm(i). Next, gAB(S) is calculated from Dm(i). Meanwhile, the coagulation reaction of the normal sample is measured to obtain P(i) of the normal sample. Here, P(i) of the normal sample is also referred to as Ps(i). D(i) of the normal sample is calculated from Ps(i). Here, D(i) of the normal sample is also referred to as Ds(i). Next, gAB(S) is calculated from Ds(i). The procedures for measuring the coagulation reaction of the mixed sample and normal sample, obtaining Pm(i) and Ps(i), and calculating Dm(i) and Ds(i) follow the procedures described above for the test sample. The procedures for calculating gAB(S) from Dm(i) and Ds(i) follow the procedures described above for the gAB(S) of the test sample.

[0042] The parameter R(S) is calculated from the gAB(S) for Dm(i) of the mixed sample, D(i) of the test sample, and Ds(i) of the normal sample according to the following equation (6): R(S) = {(gAB(S) for Ds(i)) + (gAB(S) for D(i))} / 2 - (gAB(S) for Dm(i)) (6) The R(S) of LA samples tends to be larger than that of Def samples. Therefore, if the R(S) of a test sample is larger than a predetermined threshold, the sample can be inferred to be LA. On the other hand, if the R(S) is smaller than the predetermined threshold, the sample can be inferred to be Def. The threshold can be determined based on the R(S) obtained from a known group of LA or Def samples. For example, the threshold can be set between the minimum R(S) obtained from the group of LA samples and the maximum R(S) obtained from the group of Def samples. Alternatively, the threshold can be set as the [mean value - k x SD] of R(S) for the LA sample group, or the [mean value + k x SD] of R(S) for the Def sample group (preferably k = 2 to 5).

[0043] Those skilled in the art will understand that in the procedure for estimating the causes of coagulation abnormalities described above, "above threshold" may be used instead of "greater than threshold," or "below threshold" may be used instead of "lower than threshold," as long as different causes of coagulation abnormalities can be distinguished and estimated.

[0044] The estimated results of the causes of coagulation abnormalities in the test sample obtained by the above procedure can be output in any format. For example, they can be output in the form of electronic data, printout, display on a screen, or the like. The estimated results include information on whether the test sample is normal or whether it is DOACs-positive, coagulation factor deficiency, lupus anticoagulant-positive, coagulation factor inhibitor-positive, or heparin-positive. The estimated results may also be output along with the coagulation time of the test sample, parameters reflecting the P(i), D(i) or shape of D(i) of the test sample, or the value of the parameter R(S).

[0045] 6. Application to Other Coagulation Reaction Measurement Methods The present invention has been described above using an example in which a coagulation reaction curve obtained based on the amount of scattered light is used. However, those skilled in the art will be able to apply the method of the present invention to methods using coagulation reaction curves obtained from other coagulation reaction measurement methods (e.g., coagulation reaction measurement methods based on transmittance, absorbance, viscosity, etc.). For example, an inverted sigmoid-shaped coagulation reaction curve based on the amount of transmitted light will have the opposite sign to that based on the amount of scattered light described above. In such cases, it will be clear to those skilled in the art that the sign of D(i) will be reversed in the parameter calculation; for example, the maximum value Dmax of D(i) will be replaced with the minimum value Dmin, and the calculation range will be replaced with a region satisfying D(i)≦Dmin×S(%).

[0046] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.

[0047] Reference Example) An example of the flow of procedures for estimating the cause of coagulation abnormalities is described below. (S1) Calculate the coagulation reaction curve P(i) and coagulation time (APTT) of the test sample. (S2) Calculate D(i) of the test sample. D(i) = P(i) - Pn(i). (S3) Calculate a parameter reflecting the shape of D(i). (S4) Compare APTT with the reference value. → If APTT is not prolonged, proceed to (S5). → If APTT is prolonged, proceed to (S6). (S5) Calculate parameter A [gB(S)] or parameter B [gAB(S)] for the test sample and compare it with the threshold. → If parameter A is greater than the threshold, proceed to (S11). → If parameter B is less than the threshold, proceed to (S11). → Otherwise, proceed to (S10). (S6) Calculate parameter [gAB(S)] for the test sample and compare it with the threshold. → If the parameter is smaller than the threshold, go to (S12). → Otherwise, go to (S7). (S7) Calculate the parameter [RgB(S1 / S2)] (S1<S2) for the test sample and compare it with the threshold. → If the parameter is smaller than the threshold, go to (S13). → Otherwise, go to (S8). (S8) Calculate D(i) for the mixed sample and normal sample. Calculate the following parameter R(S) from the gAB(S) for the mixed sample, test sample, and normal sample and compare it with the threshold. R(S) = {(gAB(S) of normal sample) + gAB(S) of test sample)} / 2 - (gAB(S) of mixed sample) → If the parameter is larger than the threshold, go to (S14). → If the parameter is smaller than the threshold, go to (S15). In the above flow, the order of (S6) and (S7) can be reversed. Furthermore, the calculation of D(i) for the mixed sample and normal sample in (S8) may be performed in advance (for example, in (S2)). (S10) Output the result that the test sample is normal and the APTT. (S11) Output the result that the test sample is DOACs positive and the APTT. (S12) Output the result that the test sample is Inh and the APTT. (S13) Output the result that the test sample is Hep and the APTT. (S14) Output the result that the test sample is LA and the APTT. (S15) Output the result that the test sample is Def and the APTT.

[0048] Example 1) 1) Samples Reference sample (RP): Pooled Normal Plasma from Precision BioLogic Inc. Normal sample (NP): Plasma with APTT within the reference range (24 to 39 seconds) (N=22) Abnormal samples: LA positive sample (LA): Positive Lupus Anticoagulant Plasma from George King Biomedical Inc., and plasma from an LA patient (total N=10). Coagulation factor inhibitor positive sample (Inh): Factor VIII Deficient with Inhibitor from George King Biomedical Inc., and plasma from an Inh patient (total N=9). Coagulation factor deficient samples (Def): Factor V deficient plasma, Factor VIII deficient plasma (HA), Factor IX deficient plasma (HB), Factor X deficient plasma, Factor XI deficient plasma (Factor VIII Deficient, Factor IX Deficient from George King Biomedical Inc., and patient plasma; total N = 19). DOACs positive samples (DOACs): Plasma from patients receiving DOACs (N = 5, of which 4 had APTT within the reference range). Heparin positive samples (Hep): Hep patient plasma and RP to which unfractionated heparin had been added (total N = 18). Mixed samples: 1:1 mixed plasma of the aforementioned LA and NP (N = 8), 1:1 mixed plasma of the aforementioned Def and NP (N = 6, of which 5 were HA and NP mixed plasma and 1 was HB and NP mixed plasma).

[0049] 2) Coagulation Reaction Measurement The APTT measurement reagents used were Coagpia APTT-N (manufactured by Sekisui Medical Co., Ltd.) as the first reagent and Coagpia APTT-N calcium chloride solution (25 mM calcium chloride solution, manufactured by Sekisui Medical Co., Ltd.) as the second reagent. Coagulation reaction measurements were performed using a CP3000 automated blood coagulation analyzer (manufactured by Sekisui Medical Co., Ltd.). 50 μL of sample was heated in a cuvette at 37°C for 45 seconds, after which 50 μL of the first reagent at approximately 37°C was added. After a further 171 seconds, 50 μL of the second reagent was added to initiate the coagulation reaction. The reaction was performed at 37°C. The coagulation reaction was measured by irradiating the cuvette with light at a wavelength of 660 nm from an LED light source, and measuring the amount of scattered light at a 90-degree side angle at 0.1-second intervals. The measurement time was 360 seconds.

[0050] 3) Obtaining the coagulation reaction curve P(i) After smoothing processing including noise removal was performed on the photometric data C(i) from each sample, the zero point was adjusted so that the amount of scattered light at the start of photometry was 0. The adjusted C(i) was relativized according to the above formula (1) so that the maximum value was 100, and the coagulation reaction curve P(i) was obtained.

[0051] 4) Obtaining the reference curve Pn(i) P(i) from RP was shifted so that its rising point was 10 seconds, and Pn(i) was obtained. The rising point of P(i) was detected as the point at which P(i) reached 2% of its maximum value (maximum scattered light amount). P(i) and Pn(i) of RP are shown in Figure 1.

[0052] 5) Obtaining the Deviation Curve D(i) D(i) was obtained from the P(i) and Pn(i) of each sample according to the above formula (2). Figure 2 shows the P(i) and D(i) obtained from Inh (A), Hep (B), and DOACs (C). In each figure, the left side shows the sample's P(i) together with Pn(i), and the right side shows D(i). The P(i) of Inh had a slow rise and a gradual increase, resulting in a broad peak for D(i) and a gradual decline (Figure 2A). The P(i) of Hep had a slow rise but a rapid increase, resulting in a broad peak for D(i) but a rapid rise and decline (Figure 2B). The P(i) of DOACs had a fast rise and a rapid increase, resulting in a sharp peak for D(i) (Figure 2C).

[0053] 6) Calculation of Parameters gT(S), gH(S), and gB(S) were calculated for D(i) of each sample. S was varied between 5 and 90, and gT(S) and gH(S) for each S were calculated according to the above formulas (4) and (5). The time or measurement point between t1 and t2 in formula (4) corresponding to each S that satisfied D(i) ≥ Dmax × S (%) was defined as gB(S). Furthermore, gAB(S) was calculated. The parameter R(S) was calculated according to the above formula (6) from the gAB(S) of the mixed sample and the abnormal samples and RP contained therein. Hereinafter, gT(S), gH(S), gB(S), gAB(S), and R(S) may be abbreviated as gTS, gHS, gBS, gABS, and RS, respectively, without parentheses.

[0054] 7) Prediction of DOAC-positive samples. Of the 83 samples, 26 had normal APTTs (within the reference range, not prolonged) (APTT ≤ 39). Of these, 22 were NPs and 4 were DOACs. The gB50, gB60, gB70, and gAB60 values ​​for these samples with normal APTTs are shown in Figures 3A-D. The gB50-gB70 values ​​for DOACs tended to be larger and showed a different distribution compared to other APTT-normal samples (i.e., NPs). The gAB60 values ​​for DOACs also tended to be smaller and showed a different distribution compared to other APTT-normal samples (NPs). These results demonstrate that normal samples can be distinguished from DOAC-positive samples based on gB(S) and gAB(S).

[0055] 8) Prediction of coagulation factor inhibitor-positive specimens Fifty-seven specimens had prolonged APTT (APTT > 39), of which nine specimens had Inh. Figure 4 shows the gAB05 of Inh and specimens with other factors that prolong APTT. The gAB05 of Inh tended to be smaller than that of other specimens. Based on gAB(S), it was shown that coagulation factor inhibitor-positive specimens can be distinguished from abnormal specimens with prolonged APTT.

[0056] 9) Estimation of Heparin-Positive Samples: The RgB(05 / 90) (gB05 / gB90) ratio was examined for 48 samples, excluding the 9 Inh samples from the 57 samples used in 8). Eighteen of the 48 samples were Hep. Figure 5 shows the gB05 / gB90 ratios for Hep and samples with other APTT prolonging factors. The gB05 / gB90 ratios for Hep tended to be lower than those for other samples. However, one factor X-deficient sample overlapped with the Hep distribution. It was demonstrated that heparin-positive samples could be distinguished from abnormal samples with APTT prolongation based on the ratio of gB(S) for different S, RgB(S1 / S2) (gB(S1) / gB(S2)).

[0057] 10) Estimation of LA and Def. For the 14 mixed samples, the abnormal samples (8 LA samples and 6 Def samples) and NP used in their preparation, gAB(S) was calculated when S was 5, 10, 20, 30, 40, 50, 60, 70, 80, and 90, and then R(S) was examined. R(S) for LA and Def (S = 5, 10, 20, 30, 40, 50, 60, 70, 80, and 90) are shown in Figures 6 and 7. R(S) for LA tended to be larger than that for Def. It was demonstrated that LA-positive samples could be distinguished from samples with coagulation factor deficiencies based on R(S).

Claims

1. A method for estimating causes of coagulation abnormalities in a blood sample, comprising: calculating a deviation curve D(i) of a test blood sample; calculating parameters reflecting the shape of D(i); and estimating causes of coagulation abnormalities in the test blood sample based on the parameters, wherein: D(i) = P(i) - Pn(i); i represents the number of measurement points or time; P(i) is a curve obtained by relativizing the measurement data of the coagulation reaction of the test blood sample to a minimum value of 0 and a maximum value of A; Pn(i) is a curve obtained by shifting P'(i) so that its rising point coincides with a specified point X, and P'(i) is a curve obtained by relativizing the measurement data of the coagulation reaction of a reference sample to a minimum value of 0 and a maximum value of A; A > 0; and X is 5 to 15 seconds, or the number of measurement points corresponding thereto.

2. The parameter reflecting the shape of D(i) is at least one selected from the group consisting of gT(S), gH(S), gB(S), gAB(S), and RgB(S1 / S2), where gT(S) and gH(S) are each represented by the following formula:

2. The method of claim 1, wherein t1 and t2 are the minimum and maximum values ​​of i, respectively, that satisfy D(i)≧Dmax×S(%), where Dmax is the maximum value of D(i) and 0<S<100, and, when D(i)<Dmax×S(%), i=0 and D(i)=0 are considered to be satisfied; gB(S) represents the time or number of measurement points between t1 and t2 that satisfy D(i)≧Dmax×S(%); gAB(S)=gH(S) / gB(S); and RgB(S1 / S2)=gB(S1) / gB(S2), where 0<S1<100 and 0<S2<100, with the proviso that S1≠S2.

3. The method of claim 2, further comprising calculating at least one selected from the group consisting of gB(S) and gAB(S) when the clotting time of the test blood sample is not prolonged.

4. The method of claim 3, further comprising deducing that the test blood sample is positive for DOACs if gB(S) is a threshold value or greater, or if gAB(S) is a threshold value or less.

5. The method of claim 2, further comprising calculating at least one selected from the group consisting of gAB(S) and RgB(S1 / S2) when the clotting time of the test blood sample is prolonged.

6. The method of claim 5, further comprising presuming that the test blood sample is positive for a coagulation factor inhibitor if gAB(S) is at or below a threshold value.

7. The method of claim 5, further comprising deducing that the test blood sample is heparin positive if S1<S2 and RgB(S1 / S2) is at or below a threshold value.

8. The method of claim 5, comprising: presuming that the test blood sample is positive for a coagulation factor inhibitor if gAB(S) is a threshold value or less; presuming that the test blood sample is positive for heparin if S1<S2 and RgB(S1 / S2) is a threshold value or less; and presuming that a test blood sample that is not presumed to be positive for a coagulation factor inhibitor or heparin is positive for lupus anticoagulant or has a coagulation factor deficiency.

9. The method includes preparing a mixed specimen of a test blood specimen not suspected to be positive for a coagulation factor inhibitor or heparin and a normal specimen, calculating a deviation curve Dm(i) of the mixed specimen and a deviation curve Ds(i) of the normal specimen, calculating gAB(S) for Dm(i) and Ds(i), and calculating a parameter R(S), wherein: Dm(i)=Pm(i)-Pn(i); Ds(i)=Ps(i)-Pn(i); Pm(i) is a curve obtained by relativizing the measurement data of the coagulation reaction of the mixed specimen to a minimum value of 0 and a maximum value of A; Ps(i) is a curve obtained by relativizing the measurement data of the coagulation reaction of the normal specimen to a minimum value of 0 and a maximum value of A; Pn(i) and A are as defined above; gAB(S) for Ds(i) is represented by the following formula: gAB(S) for Ds(i) = [gH(S) for Ds(i)] ÷ [gB(S) for Ds(i)], where (In formula (I), t1 and t2 are respectively the minimum and maximum values ​​of i that satisfy Ds(i) ≥ [maximum value of Ds(i) × S(%)], and 0 < S < 100, with the exception that when Ds(i) < [maximum value of Ds(i) × S(%)], it is deemed that i = 0 and Ds(i) = 0); gB(S) for Ds(i) represents the time or number of measurement points that satisfy Ds(i) ≥ [maximum value of Ds(i) × S(%)] between t1 and t2; gAB(S) for Dm(i) is represented by the following formula: gAB(S) for Dm(i) = [gH(S) for Dm(i)] ÷ [gB(S) for Dm(i)], where, The method according to claim 8, wherein in formula (II), t1 and t2 are the minimum and maximum values ​​of i, respectively, which satisfy Dm(i) ≥ [maximum value of Dm(i) × S(%)], and 0 < S < 100, with the proviso that when Dm(i) < [maximum value of Dm(i) × S(%)], then i = 0 and Dm(i) = 0 are regarded as being satisfied; gB(S) for Dm(i) represents the time or number of measurement points which satisfy Dm(i) ≥ [maximum value of Dm(i) × S(%)] between t1 and t2; and R(S) = {(gAB(S) for Ds(i)) + (gAB(S) for D(i))} / 2 - (gAB(S) for Dm(i)).

10. The method of claim 9, further comprising: presuming that the test blood sample is lupus anticoagulant positive if R(S) is at or above a threshold value; or presuming that the test blood sample is coagulation factor deficient if R(S) is at or below a threshold value.

11. The method of claim 1, further comprising calculating the clotting time of the test blood sample.

Citation Information

Patent Citations

  • Blood coagulation time measurement and device therefor

    JP1994249855A

  • Composition and method for assessing acute rejection in renal transplantation

    JP2020039344A

  • Smart control system for medical air cushion beds

    JP2020068877A

  • Analysis method, analysis device, and analysis program

    WO2020101025A1

  • Method for analyzing blood coagulation characteristics of blood specimen

    WO2020158948A1